← Back to Clinical Trials
Recruiting NCT07351305

NCT07351305 Non-Trauma Intervention to Treat PTSD for Veterans and Service Members Suffering From a TBI

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07351305
Status Recruiting
Phase
Sponsor The University of Texas Health Science Center at San Antonio
Condition PTSD
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2026-03-05
Primary Completion 2027-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Non-Trauma Treatment for TBI and PTSD

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2026-03-05 with a primary completion date of 2027-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators want to test a treatment for posttraumatic stress disorder (PTSD) especially designed for military veterans and service members with mild or moderate traumatic brain injuries (TBI) and PTSD. The treatment will include individual psychotherapy sessions to manage PTSD.

Eligibility Criteria

Inclusion Criteria: 1. Ability of participant to understand and the willingness to sign a written informed consent document based on interviewer assessment and clinical judgement. 2. Any veteran or active duty service member (age 18 or above) diagnosed with mild or moderate TBI as determined by the Ohio State University Brain Injury Identification Method 3. Participant meets diagnostic criteria for PTSD based on Clinician-Administered PTSD Scale (CAPS-5) interview as described by the National Center for PTSD which includes at least one Criterion B symptom, one Criterion C symptom, two Criterion D symptoms, and two Criterion E symptoms as well as meeting Criterions F and G. 4. Ability to read, write, and speak English based on interviewer assessment and clinical judgement. Exclusion Criteria: 1. Participant is actively engaged in a behavioral intervention primarily targeting PTSD. 2. Participant has a psychiatric problem that warrants immediate treatment as indicated in the electronic health record, flagged during testing, or confirmed by a clinician through screening or review of clinical notes. 3. Participant demonstrates significant cognitive impairment that could impact treatment adherence/benefit based on interviewer assessment and clinical judgement.

Contact & Investigator

Central Contact

Cindy McGeary, PhD

✉ mcgearyc@uthscsa.edu

📞 210-567-5497

Principal Investigator

Cindy McGeary, PhD

PRINCIPAL INVESTIGATOR

The University of Texas Health Science Center at San Antonio

Frequently Asked Questions

Who can join the NCT07351305 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying PTSD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07351305 currently recruiting?

Yes, NCT07351305 is actively recruiting participants. Contact the research team at mcgearyc@uthscsa.edu for enrollment information.

Where is the NCT07351305 trial being conducted?

This trial is being conducted at Fort Hood, United States.

Who is sponsoring the NCT07351305 clinical trial?

NCT07351305 is sponsored by The University of Texas Health Science Center at San Antonio. The principal investigator is Cindy McGeary, PhD at The University of Texas Health Science Center at San Antonio. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology